Genetic Technologies (ASX: GTG) has entered an agreement with German diagnostic product developer AutoImmun Diagnostika, which has been granted non-exclusive rights to a number of Genetic’s patents covering its non-coding DNA technology.
The agreement provides AutoImmun Diagnostika non-exclusive access to Genetic’s non-coding DNA technology for its products and services.
Genetic is also in ongoing discussions with companies relating to the use of its non-coding DNA technology.
Cancer Diagnostics
Genetic is using the latest technology to identify changes in DNA to either confirm a diagnosis of a specific disorder of which a person displays signs or symptoms, or to identify individuals at risk of developing a disease before any symptoms appear.
The company is aiming to establish itself as a cancer diagnostics business and the first product launched as part of this strategy is the BREVAGen™ breast cancer risk stratification test.
BREVAGen™, which was launched in the U.S. in June, is a novel genetic test panel that examines a patient's DNA to detect the absence or presence of certain common genetic variations associated with an increased risk for developing breast cancer.
The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient's family and personal history, therefore giving a clearer picture of an individual woman's risk of developing breast cancer.